Cite
MLA Citation
S. Z. Usmani et al.. “Cost-effectiveness of lenalidomide plus dexamethasone vs bortezomib plus melphalan and prednisone in transplant-ineligible US patients with newly-diagnosed multiple myeloma.” Journal of medical economics, vol. 19, 2016, pp. 243–258. http://access.bl.uk/ark:/81055/vdc_100031798933.0x000063